Promising science has the potential to combat rising antibiotic resistance—but too often, it never reaches patients due to a long and difficult development path. To change that, I co-founded Arivin therapeutics with three experienced, ambitious partners and now serve as CEO. I hold an MSc in Biotechnology from the University of Edinburgh and a PhD from Aalto University (Summa Cum Laude), during which I also worked as a visiting scholar at Stanford University’s Division of Pulmonary Medicine, deepening my expertise in drug development. At Arivin Tx, I’ve helped secure over €5M in equity and non-dilutive funding to advance our bold and novel Future-Proof therapies targeting some of the most resistant infections of our time, including Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.